Disease Landscape and Forecast 인사이트

The approval two CAR T-cell therapies for relapsed / refractory B-cell hematological malignancies—Novatis’ Kymriah for acute lymphoblastic leukemia (ALL) and large B-cell lymphoma and Kite…

Breast cancer is the most commonly diagnosed cancer among Chinese women. A high incidence and a prolonged treatment duration make the treatment of breast cancer a lucrative commercial opportunity…

For decades, the treatment landscape of small-cell lung cancer (SCLC) has been dominated by chemotherapy or chemoradiotherapy. In 2018, BristolMyers Squibb’s Opdivo became the first immune…

Sjögren’s syndrome (SS) is a progressive autoimmune disease characterized by chronic inflammation and lymphocytic infiltration of the exocrine glands that may occur alone (primary SS) or with a…

The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 520 currently available and novel biosimilar products, detailing…

Systemic sclerosis (SSc) is a rare, progressive, debilitating autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that manifests as Raynaud’s disease, skin…

The approval of Shanghai Henlius Biotech’s HLX01—a biosimilar of Roche’s Rituxan (rituximab)—in February 2019 marked the beginning of the biosimilars era in China. Since then, biosimilars of…

Focal segmental glomerulosclerosis (FSGS) is a kidney disease in which scarring occurs to the glomeruli. Patients with FSGS typically present with nephrotic syndrome, involving edema and…

Immune checkpoint inhibitors have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as a versatile weapon against cancer. The approval of…

Dry eye disease (DED) is a chronic, inflammatory, and highly heterogeneous condition of the eye; it is also referred to as dry eye syndrome or keratoconjunctivitis sicca. Although DED represents a…

Atopic dermatitis is a common skin disease that significantly affects quality of life. For many years, atopic dermatitis treatment in China included only conventional topical/systemic agents and no…

The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, along with conventional treatments, makes the rheumatoid…